Evome Medical Technologies Inc.
LNDZF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 9.89% |
| EV / EBITDA | 13.88 | -13.32 | -8.33 | -2.65 |
| Quality | ||||
| ROIC | -3.25% | -7.11% | 0.00% | 0.00% |
| Gross Margin | 35.58% | 31.47% | 32.53% | 35.22% |
| Cash Conversion Ratio | -1.55 | -1.37 | 0.14 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.62% | 27.81% | 51.77% | 87.35% |
| Free Cash Flow Growth | -43.50% | 580.02% | -157.48% | 673.51% |
| Safety | ||||
| Net Debt / EBITDA | 13.88 | -13.32 | -8.33 | -1.79 |
| Interest Coverage | -0.91 | -2.19 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.70 | 0.70 | 0.77 | 0.99 |
| Cash Conversion Cycle | 105.89 | 122.18 | 120.26 | 85.79 |